对联合全身BRAF/MEK抑制剂有反应的结膜黑色素瘤
Conjunctival Melanoma Responsive to Combined Systemic BRAF/MEK Inhibitors.
作者信息
Dagi Glass Lora R, Lawrence Donald P, Jakobiec Frederick A, Freitag Suzanne K
机构信息
*Ophthalmic Plastic Surgery Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School; †Cancer Center, Massachusetts General Hospital, Harvard Medical School; and ‡Department of Ophthalmology, David C. Cogan Laboratory of Ophthalmic Pathology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, U.S.A.
出版信息
Ophthalmic Plast Reconstr Surg. 2017 Sep/Oct;33(5):e114-e116. doi: 10.1097/IOP.0000000000000833.
This report demonstrates a unique case of conjunctival melanoma harboring a BRAF V600E mutation responsive to systemic therapy with BRAF and MEK inhibitors. While systemic therapy would not be appropriate in patients with local disease alone, it may act therapeutically in cases of higher stage ocular surface and eyelid melanoma.
本报告展示了一例独特的结膜黑色素瘤病例，该病例携带BRAF V600E突变，对BRAF和MEK抑制剂的全身治疗有反应。虽然全身治疗仅对局部疾病患者不合适，但在较高分期的眼表和眼睑黑色素瘤病例中可能具有治疗作用。
Zotero 插件